利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

184 条记录 (耗时 0.028 秒)

    Method of preparing and using isoflavones for the treatment of blood related illnesses
    41.
    发明授权
    Method of preparing and using isoflavones for the treatment of blood related illnesses 失效
    制备和使用异黄酮治疗血液相关疾病的方法

    公开(公告)号：US06391308B1

    公开(公告)日：2002-05-21

    申请号：US09615239

    申请日：2000-07-13

    申请人： Mark Empie ,  Eric Gugger

    发明人： Mark Empie ,  Eric Gugger

    IPC分类号： A01N6500

    CPC分类号： C07D311/36 ,  A23L33/105 ,  A23L33/11 ,  A23V2002/00 ,  A61K36/185 ,  A61K36/48 ,  A61K36/488 ,  A61K36/55 ,  A61K36/68 ,  A61K36/82 ,  A61K36/899 ,  Y10S514/823 ,  Y10S514/824 ,  Y10S514/874 ,  Y10S514/899 ,  Y10S514/923 ,  A61K2300/00 ,  A23V2250/2116 ,  A23V2250/2132

    摘要： A composition is prepared by extracting phytochemicals from plant matter and is administered to provide treatment for cardiovascular medical conditions, such as: excessive bloodstream cholesterol, the risk of heart disease, abnormal blood lipid profiles, and abnormal vascular effects. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. The isoflavones are selected from a group including malonyl, acetyl, glucoside and aglycone. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The composition is a dietary supplement in a concentrated form, preferably in an easy to consume form, for treatment of various cardiovascular conditions and various other related disorders.

    摘要翻译： 通过从植物物质提取植物化学物质来制备组合物，并施用以提供心血管医学病症的治疗，例如：血液过度胆固醇，心脏病的风险，血脂异常和血管异常异常。 该组合物优选富含植物物质的两个或更多个部分，即异黄酮，木脂素，皂角苷，皂草苷，儿茶素和酚酸。 异黄酮选自包括丙二酰，乙酰，葡糖苷和糖苷配基的组。 大豆是这些化学品的首选来源; 然而，也可以使用其它植物，例如小麦，欧车前，大米，燕麦，红三叶草，葛，苜蓿，亚麻和可可。 该组合物是浓缩形式的膳食补充剂，优选易于消费形式，用于治疗各种心血管疾病和各种其它相关疾病。

    Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
    47.
    发明授权
    Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith 失效
    低熔点可成型药物赋形剂和剂型

    公开(公告)号：US5244668A

    公开(公告)日：1993-09-14

    申请号：US930325

    申请日：1992-08-17

    申请人： Wallace C. Snipes

    发明人： Wallace C. Snipes

    IPC分类号： A61K9/00 ,  A61K9/02 ,  A61K9/20

    CPC分类号： A61K9/02 ,  A61K9/006 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  Y10S514/813 ,  Y10S514/874 ,  Y10S514/953 ,  Y10S514/96 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/969

    摘要： An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________ The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

    摘要翻译： 用于在体温下熔化但不会在运输和储存中遇到的较高温度下自发变形的药物化合物的赋形剂包括：低分子量聚乙二醇75-90％ - （MP约37℃） - 中等高分子量聚乙烯 乙二醇0-4％ - 长链饱和羧酸0-4％ - 聚环氧乙烷0-4％ - （MW 100,000-5,000,000）胶体二氧化硅10-20％。 - 赋形剂特别有利于制备用于口服给予药物化合物的剂型。

    Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same
    50.
    发明授权
    Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same 失效
    雄甾烷和雌二醇系的支链和脂环族酯以及含有它们的药物组合物

    公开(公告)号：US4212864A

    公开(公告)日：1980-07-15

    申请号：US852326

    申请日：1977-11-17

    申请人： Lambert J. W. M. Tax

    发明人： Lambert J. W. M. Tax

    IPC分类号： A61K31/565 ,  C07J1/00 ,  C07J43/00

    CPC分类号： C07J1/0074 ,  C07J1/0025 ,  Y10S514/874

    摘要： There are disclosed branched chain and cycloaliphatic esters of steroids having the formula: ##STR1## or the 5.alpha.H analog thereof, where R is H or CH.sub.3 ;R.sub.1 is H or CH.sub.3 ;R.sub.2 is H or CH.sub.3 ;R.sub.3 is H, OH, CH.sub.3 or Cl;R.sub.4 is H or C.sub.1 to C.sub.4 alkyl;R.sub.5 is H, C.sub.1 to C.sub.4 alkyl or CF.sub.3 ;R.sub.6 is H, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy, halogen or .beta.-OH providing that when R.sub.6 is .beta.-OH, the steroid also contains 9.alpha.-F and further providing that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent at least 4 and at most 5 hydrogen atoms, except in the case of a .DELTA..sup.1,4 -steroid, in which case R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are all hydrogen;R.sub.7 is H or CH.sub.3 ; ##STR2## providing the R.sub.8 is --OH or ##STR3## when the steroid has an aromatic ring A and the 3-position is substituted by ##STR4## R.sub.9 is ##STR5## where n is 0, 1 or 2;R.sub.10 is C.sub.1 to C.sub.10 alkyl;R.sub.11 is H or C.sub.1 to C.sub.10 alkyl;R.sub.12 is an aliphatic group with 1 to 18 carbon atoms, or R.sub.10 and R.sub.12 taken together with the carbon atom to which they are attached form a C.sub.7 to C.sub.12 cycloaliphatic group providing the total carbon atom content in the carboxylic acid residue is 8 to 20;ring A is either saturated or has one of the following types of unsaturation: .DELTA..sup.1 ; .DELTA..sup.4 ; .DELTA..sup.1,4 ; .DELTA..sup.5(10) ; .DELTA..sup.1,3,5(10), andX is .dbd.O, --OH or ##STR6## providing that X is OH or ##STR7## when the steroid has an aromatic ring A. The steroid esters have androgenic, anabolic, oestrogenic or anti-oestrogenic properties depending upon the ring configurations and the substituent(s). Pharmaceutical compositions containing the steroid esters are also disclosed.

    摘要翻译： 公开了具有下式的类固醇的支链和脂环族酯：其中R是H或CH 3; R1是H或CH3; R2是H或CH3; R3是H，OH，CH3或Cl; R4是H或C1-C4烷基; R5是H，C1-C4烷基或CF3; R6为H，C1至C4烷基，C1至C4烷氧基，卤素或β-OH，条件是当R6为β-OH时，类固醇还含有9个α-F，并进一步提供R1，R2，R3，R4，R5和 R6代表至少4个和至多5个氢原子，除了在DELTA1,4-甾类的情况下，其中R1，R2，R3，R4，R5和R6都是氢; R7是H或CH3; 当类固醇具有芳香环A并且3位被 R9取代时，提供R8是-OH或，其中n是0,1或2; R10为C1〜C10烷基; R11为H或C1〜C10烷基; R12是具有1至18个碳原子的脂族基团，或者R10和R12与它们所连接的碳原子一起形成C7至C12脂环族基团，其中羧酸残基中的总碳原子含量为8至20; 环A饱和或具有以下不饱和度之一：DELTA 1; DELTA 4; DELTA 1,4; DELTA 5（10）; DELTA 1,3,5（10），X为= O，-OH或，当类固醇具有芳环A时，X为OH或“IMAGE”。类固醇酯具有雄激素，合成代谢，雌激素或 取决于环构型和取代基的抗雌激素特性。 还公开了含有类固醇酯的药物组合物。